Our findings demonstrated a generalized upregulation of HDAC5 and HDAC6 genes in HaCaT, HepG2, and A549 after treatment exposure with TRZ, indicating that HDAC5 and HDAC6 are potential lung, liver, and skin cancers therapeutic targets and prognostic biomarkers. The gene discussed is HDAC6; the disease is skin cancer.